Earnings picture during a key regulatory phase

Vera Therapeutics (VERA) reported a first quarter net loss of US$121.03 million, compared with US$51.69 million a year earlier, as it pushes atacicept toward potential approval for IgA nephropathy.

Basic and diluted loss per share from continuing operations came in at US$1.69, versus US$0.81 in the prior year period. This provides a snapshot of how much capital the company is currently investing ahead of the July 7, 2026 FDA decision.

Vera Therapeutics' share price has pulled back recently, with a 30 day share price return of a 10.30% decline and a year to date share price return of a 26.20% decline. However, the 1 year total shareholder return of 62.87% and very large 3 year total shareholder return suggest longer term momentum has been strong as investors weigh the FDA priority review and wider losses.

If you are watching how regulatory milestones move biotech stocks, it can also be useful to scan for other healthcare companies using advanced AI. You can start with 35 healthcare AI stocks

With the stock trading at US$35.88 and carrying a very large implied discount to both analyst targets and intrinsic value estimates, investors now have to ask: is this a buying opportunity, or is the market already pricing in future growth?

Preferred price to book of 4.3x: Is it justified?

On the numbers, Vera Therapeutics looks expensive on a P/B basis, with its 4.3x multiple sitting above both the US biotechs industry average of 2.5x and the peer average of 3.8x, even as the stock last closed at $35.88.

The P/B ratio compares the share price with net assets per share. This tends to matter for early stage or loss making biotechs where traditional earnings ratios are less useful. A higher P/B can signal that the market is placing a premium on the company’s pipeline, future cash flows or balance sheet strength relative to the accounting book value.

Here, the premium multiple sits alongside several other signals investors often weigh together. Vera is currently unprofitable, reports a loss of $299.62m and has a negative return on equity of 49.56%, while losses over the past 5 years have grown at 36% per year. At the same time, analysts expect revenue to grow at 51.3% per year and earnings at 59.6% per year, and the SWS DCF model suggests the stock is trading at a very large discount to its estimated future cash flow value of $442.

Against that backdrop, the P/B of 4.3x suggests the market is already pricing in a materially richer future than what the industry average implies. It is, however, still materially below what the DCF framework indicates could be justified if those cash flow forecasts play out.

Result: Price to book of 4.3x (OVERVALUED)

However, there are still clear risks here, including the company’s US$299.62m loss and US$0 revenue base if expectations around atacicept or funding needs change.

Another view on value: DCF vs P/B

While the 4.3x P/B multiple looks expensive next to the US biotechs industry at 2.5x and peers at 3.8x, the SWS DCF model points the other way. It shows a future cash flow value of $442 per share compared with the current $35.88 price. So is this a value trap or a valuation gap?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Balancing strong past returns with current losses and regulatory uncertainty is never straightforward. It helps to move quickly, review the data for yourself, and then check the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with a single biotech stock. Use focused stock lists to spot opportunities before they feel obvious.

• Zero in on potential bargains by scanning 51 high quality undervalued stocks that combine quality with pricing that may look attractive on key fundamentals.
• Prioritise resilience and sleep a little easier at night by checking 72 resilient stocks with low risk scores that score well on financial strength and risk factors.
• Get ahead of the crowd by researching screener containing 23 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.